Sugi Predict

Sugi Predict / Compounds / SCHEMBL859685

SCHEMBL859685

SCHEMBL859685

C[Si](C)(C)CCOCn1ccc2c(-c3cc[nH]c3)ncnc21

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.35
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP19A1 P11511 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ TPH1 P17752 1/20 0.32
▸ AKT1 P31749 1/20 0.31
▸ ROCK1 Q13464 1/20 0.31
▸ DUT P33316 1/20 0.31
▸ EGFR P00533 1/20 0.31
▸ IGF1R P08069 1/20 0.31
▸ SRC P12931 1/20 0.31
▸ FLT4 P35916 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ EPHB4 P54760 1/20 0.31
▸ TEK Q02763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22826667 0.90 CYP1A2 (0.34) DGAT1CYP1A2CYP3A4CYP2D6CYP19A1
SCHEMBL31089960 0.85 SIGMAR1 (0.40) DGAT1TPH1
SCHEMBL99142 0.85 SIGMAR1 (0.40) DGAT1TPH1
SCHEMBL29710434 0.85 TPH1 (0.41) DGAT1TPH1EGFRIGF1RSRC
SCHEMBL30446012 0.85 TPH1 (0.41) DGAT1TPH1EGFRIGF1RSRC
SCHEMBL30445481 0.84 SIGMAR1 (0.36) DGAT1CYP3A4CYP2D6TPH1
SCHEMBL30445095 0.84 SIGMAR1 (0.38) DGAT1CYP1A2CYP3A4TPH1
SCHEMBL17387449 0.84 SIGMAR1 (0.39) DGAT1TPH1
SCHEMBL12262948 0.83 DGAT1 (0.35) DGAT1CYP1A2CYP3A4CYP2D6CYP19A1
SCHEMBL18975931 0.83 DGAT1 (0.35) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4400172-A2 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS Incyte Holdings Corporation (US) 2024-07-17 — — EP disclosed
EP-4036088-B1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE HOLDINGS CORP (US) 2024-04-03 — — EP disclosed
US-20230043959-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION 2023-02-09 — — US disclosed
US-20230043959-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION 2023-02-09 — — US disclosed
US-20220378791-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2022-12-01 — — US disclosed
US-11285140-B2 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors INCYTE CORPORATION (US) 2022-03-29 — — US disclosed
WO-2021254133-A1 SMALL MOLECULE COMPOUND 嘉兴特科罗生物科技有限公司 2021-12-23 — — WO disclosed
EP-3715347-B1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE HOLDINGS CORP (US) 2021-12-22 — — EP disclosed
US-20210069193-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2021-03-11 — — US disclosed
US-20200397774-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE HOLDINGS CORPORATION 2020-12-24 — — US disclosed
US-20110224190-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION 2011-09-15 — — US disclosed
US-20110224190-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION 2011-09-15 — — US disclosed
WO-2011112662-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION (US) 2011-09-15 — — WO disclosed
WO-2011028685-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2011-03-10 — — WO disclosed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US disclosed
EP-2288610-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS Incyte Corporation (US) 2011-03-02 — — EP disclosed
WO-2010135650-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2010-11-25 — — WO disclosed
US-20100298334-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2010-11-25 — — US disclosed
WO-2009114512-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 — — WO disclosed
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298334-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 DGAT1 4245/4885CYP1A2 1401/4885CYP3A4 2137/4885
US-20220378791-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 DGAT1 3554/4885CYP1A2 3056/4885CYP3A4 3794/4885
US-20210069193-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 DGAT1 3554/4885CYP1A2 3056/4885CYP3A4 3794/4885
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 DGAT1 4139/4885CYP1A2 2402/4885CYP3A4 2015/4885
US-20200397774-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS JAK1, JAK2, JAK3 DGAT1 3375/4885CYP1A2 2516/4885CYP3A4 2834/4885
US-20090233903-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 DGAT1 4058/4885CYP1A2 1449/4885CYP3A4 2817/4885
US-20110224190-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS JAK1, JAK2, JAK3 DGAT1 3375/4885CYP1A2 2516/4885CYP3A4 2834/4885
US-11285140-B2 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors JAK1, JAK2, JAK3 DGAT1 3375/4885CYP1A2 2516/4885CYP3A4 2834/4885
US-20230043959-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS JAK1, JAK2, JAK3 DGAT1 3473/4885CYP1A2 1964/4885CYP3A4 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.